In addition, by upregulating the transcription of Cpt1a, Pparα, Mcad, Acsl, and Ppargc1a, it has been demonstrated that fexaramine, an agonist of FXR, contributes to alleviating insulin resistance and lipid accumulation in NAFLD mice (60). This evidence concerns the gene PPARGC1A and metabolic dysfunction-associated steatotic liver disease.